Postprocessing Neuroimaging methods in MRI and PET/MRI

with applications to Multiple Sclerosis and other Neurological diseases by Poggiali, Davide
	Sede Amministrativa: UNIVERSITÀ DEGLI STUDI DI PADOVA
Dipartimento di SCIENZE CARDIOLOGICHE, TORACICHE E VASCOLARI
Corso di Dottorato in Scienze Mediche, Cliniche e Sperimentali
Curriculum Neuroscienze
XXIX Ciclo
Tesi di Dottorato
Postprocessing Neuroimagingmethods
in MRI and PET/MRI
with applications to Multiple Sclerosis and other Neurological diseases
Tesi redatta con il contributo finanziario di Teva Italia Srl.
Coordinatore: Ch.mo Prof. Gaetano Thiene
Supervisore: Ch.ma Prof.ssa Elena Pegoraro
Co-Supervisore: Ch.mo Prof. Paolo Gallo
Valutatori: Ch.ma Prof.ssa Matilde Inglese
Ch.mo Prof. Wolfgang Erb
Dottorando: Dr. Davide Poggiali
Matricola: 1084981
A.A. 2016/17

Ai miei nonni.
Vittoria (1922-2004), che ricordo solo cantare, e una
volta, ridere.
Mario (1921-2016), presenza silente, paziente, mite. E
ultimamente, incline a commuoversi in modo conta-
gioso.
Angela (1942-2009), passionaria, dissennata, generosa
e (le piaccia o meno) testimone di fede.
Riccardo (1933-), militante, riflessivo, comunicativo, ha
da poco imparato a usare WhatsApp.
i
ii
Ringraziamenti
Desidero ringraziare mia moglie Silvia, per la sua pazienza
nei miei confronti; ringrazio anche la mia e la sua famiglia di
origine, così diverse in (quasi) tutto, ma rispettose e accoglienti
per entrambi.
Ringrazio gli amici, daimateamici fiorentini a quelli padovani.
Ringrazio inoltre chi mi ha dato fiducia in ambito professio-
nale: il mio Relatore di tesi Triennale a Firenze, prof. Villari,
chemi ha insegnato l’importanza di cercare un senso profondo
al proprio lavoro e mi ha attaccato la passione per le citazioni
letterarie; il mio Relatore di tesi Magistrale a Padova, prof. De
Marchi, che mi ha sostenuto in tutto quel che ho fatto dalla
tesi in poi e mi ha spinto a continuare gli studi con il dottorato
di ricerca; il prof. Cecchin, che mi segue dalla Tesi Magistrale e
che ancora non si è stancato del sottoscritto; il prof. Gallo che
mi ha seguito e incoraggiato costantemente.
Ringrazio inoltre tutti i Colleghi del Centro di Sclerosi Multipla
di Padova, del Dipartimento di Neuroscienze e di Neuroradi-
ologia, tutti gli infermieri e la squadra dei tecnici TSRM, che
hanno sopportato la mia pur gentile insistenza e cocciutag-
gine, e senza i quali queste pagine non esisterebbero. Un sentito
ringraziamento a tutte segretarie i cui pazienti consigli sono
stati un aiuto indipensabile per districarmi fra le maglie delle
pratiche burocratiche.
Non posso inoltre non ringraziare i pazienti le cui immagini
hanno transitato davanti al mio schermo. La loro sofferenza,
che intuisco da queste immagini è per me fonte di paura, per-
plessità, ma anche di riflessione profonda e di speranza.
iii
iv
List of most used acronyms
AD Alzheimer’s Disease
CNS Central Nervous System
CSF CerebroSpinal Fluid
GM Grey Matter (UK, US: Gray Matter)
MRIMagnetic Resonance Imaging
MSMultiple Sclerosis
PET Proton Emission Tomography
WMWhite Matter
v
vi
Synopsis
Many non-invasive imaging instruments have been developed in the last 40 years,
allowing to obtain images of the interior human body while the patient is still alive. In
the context of Neurology studies, imaging systems as CT, MRI, SPECT or PET allows to
obtain biomarkers useful to quantitatively distinguish between healthy and unhealthy
subjects, evaluate the staging of aNeurological illness in a patient, evaluate the efficacy
of a treatment, explore the causes of the illness.
In this work MRI and PET imaging system are introduced from scratch, going from
reconstruction from raw data to state-of-the art post-processing techniques and the
computation of more popular biomarkers.
After this introduction, three original works using the recent PET/MRI imaging system
are presented, with a particular focus on the methods. These three studies involve
patients with Multiple Sclerosis, Alzheimer’s Disease and Brain Tumor.
Riassunto
Negli ultimi 40 anni sono stati sviluppati diversi strumenti di imaging non-invasivi,
consentendo di ottenere immagini dell’interno del corpo umanomentre il paziente è
ancora in vita. Nel contesto neurologico, sistemi di imaging come TAC, RM, SPECT e
PETpermettono di ricavare biomarcatori utili a distinguere quantitativamente soggetti
sani da pazienti conmalattie neurologiche, valutare lo stato di avanzamento di una
malattia in un paziente, valutare l’efficacia di un trattamento, esplorare le cause della
malattia.
Nel presente lavoro si presentano i sistemi di acquisione di immagini RM e PET fin
dalle fondamenta, partendo dai metodi di ricostruzione dell’immagine dai dati grezzi,
fino allo stato dell’arte dei metodi di post-processing per il calcolo dei biomarcatori
più diffusi.
Dopo tale introduzione saranno presentati tre lavori originali di imaging PET/MRI,
con una particolare attenzione ai metodi. Questi tre lavori riguardano pazienti con
Sclerosi Multipla, Morbo di Alzheimer e Tumori Cerebrali.
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Introduction
The preface is that part of a book which is written last, placed first,
and read least. As I approach my concluding task I am moved to
reflect why a preface should be written at all. This question, if
followed into all the intricacies of which it holds potentiality, should
apparently result in a composition new in literature, a Preface to the
Preface.
Alfred J. Lotka, Elements of Physical Biology
A
modern neurological study aims to relate several biomarkers from differ-
ent sources in order to explain the illness evolution, improve prognostic
accuracy and optimize the treatment. A research group can have at dis-
posal clinical, imaging, neuropsychological, liquor biomarkers, which
have shown several interesting relations with other kind of biomarkers.
Neuroimaging offers a fecund and interesting source of biomarkers. Since at
present time images of the brain can be obtained in a non-invasive way, somemea-
surements of both morphological and functional features of the brain can be taken in
vivo. Since morphological and functional images are both needed in Neuroimaging
studies [1], the past 5 years of technological development have seen the rise of hybrid
systems.
The focus of this document is on the methods for calculate biomarkers from neu-
roimages data source as Magnetic Resonance Imaging (MRI) and PET/MRI (hybrid
between PET andMRI), with some application of these methods being presented as
neurological studies. PET/MRI is a recent imaging system able to acquire MRI and
PET images at the same time, allowing the researcher to obtain a perfectly matched
PET andMRI couple of images, thus reducing significantly the biases frommovement
and the total scanning time.
Computing biomarkers from Neuroimaging sources can be very time-consuming,
also because an increasing number of images can be available from a single patient.
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For instance, a study involving three 3D (no more than 1×1×1 mm3 of resolution)
and two 2DMRI sequences and a 3D dynamic brain PET of 50 patients occupy more
than 2Tb of disk space, which can be considered as a Big Data problem [2].
Hence there is need of improving the speed of the algorithms for biomarker extraction
without loss of accuracy whenever it is possible. Furthermore, the reliability of the
method is important to avoid the wrong conclusions, as remarked by recents works [3].
Since the methods and the pipelines used in neurological studies are a constant work-
in-progress, in this work current state-of-the-art and some personal contributions will
be presented.
The document is structured as follows: the first Chapter contains an overview
onMultiple Sclerosis (MS) and other neurological diseases. In the second and third
Chapter MRI and PET will be introduced from a physical/mathematical point of view.
The concepts introduced in these two Chapters will be useful to understand the most
important algorithms used in Neuroimaging, presented in the fourth Chapter.
At last, Chapters 5, 6 and 7 contains the personal contribution of this work, which
can be summarized as a reliable method (and some variants) for PET/MRI biomarker
extraction and its application to Multiple Sclerosis (MS, CHapter 5), Alzheimer’s Dis-
ease (AD, Chapter 6) and Brain Tumors (Chapter 7).
The method relies upon a 2-phase PET/MRI (early and latter phase) which has been
projected for twomain purposes:
• First, to mimic and discern the behavior of the tracers used in PET, whose signal
is usually growing quickly in the early phase of uptake and almost constant (all
signals are corrected for decay of course) in the latter phase.
• Second, to achieve an exam that the patient could tolerate more easily. In fact
two sessions of 20 minutes circa with an intermediate rest time of 20 min is suf-
ficient to obtain a signal as significant as the full 1 hour exam for the biomarker
computation purposes.
This approach leads to a postprocessing pipeline that can be applied, after proper
adjustments, both to static PET images as in Chapter 6 and to dynamical PET series as
in Chapters 5 and 7. Other choices different from the state-of-the-art pipelines will be
explained in detail right after their introduction in Chapters 5, 6 and 7.
The statistical results of the clinical studies in the last three Chapters will also be
2
presented, along with the discussion of such results, attempting to recover a meaning-
ful and clinically-consistent interpretation of the data.
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Chapter 1
Multiple Sclerosis and other
neurological diseases
“This is Knobloch reporting that a terrible mistake has beenmade.
You were accidentally assigned to an experimental canister. The
canister you’ve been occupying is actually a giant sensor. It records
your heartbeat, your electrical brain activity, your oxygen intake,
your eye movements, your cerebral blood flow and countless other
functions that can be studied on EEG and similar tracings. Say “I
read” if you read what I’m saying.”
“I read.”
“Nobody’s supposed to occupy that canister except on an exper-
imental basis. You were put in there accidentally. The room is
extensively shielded from outside interference. The walls, the floors
and all the furniture are equipped with extremely superfine sensing
devices. The only way you could avoid being traced would be to
suspend yourself in midair. Literally everything you’ve done has
been recorded, measured and studied. Except we didn’t know until
now that the tracings we’ve been getting belong to you.”
“I read but do not understand.”
Don DeLillo, Ratner’s Star, 1976
N
eurological diseases, or neurological disorders are the medical condi-
tions involving the human brain. This chapter contains a brief introduc-
tion to some neurological diseases as Multiple Sclerosis (MS, Section 1),
Alzheimer’s Disease (AD, Section 2) and Brain Tumors in Section 3. In
these Sections the most important features of each disease are explained.
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1.1 Multiple Sclerosis
Multiple Sclerosis is a inflammatory, chronic, neurodegenerative disease involving
both White Matter (WM) an Grey Matter (GM) of the Central Nervous System (CNS).
It represents the first cause of non-traumatic disability in the young adult[4], and in
Italy the prevalence is estimated around 140 cases over 100 000 inhabitants[15].
The exact causes and underlying immunopathogenetic mechanisms of the short and
long-term damages inMS are not yet fully known. However there are several evidences
of genetical and environmental factors contributing to the loss of tolerance to myelin
antigenes and to the development of an autoimmune response to the CNS[7].
MS is characterized by the presence and appearance of plaques of inflammation1.
The inflammation is believed to be caused by an apparently random activation of
microglia cells (part of the CNS immune system) and it causes demyelinization and by
consequence neurodegeneration, which is faster in MS patients than in normal aging
healthy subjects. MS has different stages and clinical subtypes[4]: Clinically Isolated
Syndrome (CIS) are patients with the first symptoms andMRI evidences, but not or
not yet enough proves to get MS diagnosis. Relapse-RemittingMS (RRMS) are patients
with episodes of clinical and cognitive relapse, followed by a phase of reprise. Primary
and Secondary Progressive MS (PPMS, SPMS) are patients with no signs of relapse and
remit, but a continuous and constant worsening from clinical and cognitive points of
view. PPMS develop such characteristic from the beginning of the illness, while SPMS
after a period of relapse and remit.
1.1.1 WM and GM damage inMRI
It is possible to detect areas afflicted with demyelinization with specific sequences of
MRI imaging. Such areas are also referred as lesions.
The most used sequence for detecting WM lesion is called Fluid Attenuated Inversion
Recovery (FLAIR), a T2-weighted sequence who aims to suppress the signal of CSF. In
such sequence most of MSWM lesions appear as hyper-intense signal[1]. About 30%
of FLAIR detectable lesions appear as hypo-intense in T1-weighted images[17]. Such
lesions are characterized by loss of tissue, and are called black holes[2].
MS is still considered as a prevalently WM disease: diagnostic criteria currently in
use require evidences of WM lesions. However recent publications have shown the
importance of GM inflammatory lesions in the accumulation of clinical and cognitive
disability. Signs of cortical relapses have been found in some patients at early stage[22],
suggesting that the GM involvement in inflammation might closely follow or precede
WM inflammation process.
1from which the French name Sclerose a Plaques and the former Italian denomination Sclerosi a
Placche.
8


no sign of patient improvement [24].
The most popular hypothesis [11] about the illness process refers that that amyloid
accumulation leads to a cascade characterized by abnormal tau aggregation, synaptic
dysfunction, cell death, and brain shrinkage.
1.3 Brain Tumors
In Europe and in the US the incidence of primitive cerebral tumors is up to 10 over
100 000 people each year [26], with peak of prevalence between 0 and 4 years and 65
and 79 years [12]. Gliomas are about 40% of cerebral tumors and develops in the glia
cells, support cells for CNS. Tumors are rated in grades according to malignity and
spread speed. Tumors of grade III and IV, for whom the survival time goes from 13 to
36 months, are called high grade.
Treatment of brain tumor includes:
• neurosurgery, aimed to physically remove the tumor mass. Complete removal
of tumor tissue through surgery is possible only in few cases, so the goal of
such intervention is mostly to obtain an histological diagnosis and to reduce the
tumor mass and its eventual pressure.
• radiotherapy, aimed to reduce the tumor mass with a targeted exposure. Radio-
therapy can lead to cognitive decline, because it is impossible in practice to hit
only the areas of brain affected by the tumor.
• chemotherapy, which has been shown to increase the survival time by 2.5
months.
All these steps strongly depend on imaging techniques to identify the tumor areas
and the post-surgery relapse. The treatment can achieve the goal of somemonths of
survival in high grade tumors, the complete removal of the tumor in low grades.
11
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Chapter 2
Magnetic Resonance Imaging
“Interesting you should call just now. Because I’m clipping my
toenails into a wastebasket several meters away.”
“Jesus, you know how I hate the sound of nail clippers.”
“Except I’m shooting seventy-plus percent. The little fragments of
clipping. It’s uncanny. I keep wanting to go out in the hall and get
somebody in here to see it. But I don’t want to break the spell.”
“The fragile magic-spell feel of those intervals where it feels you just
can’t miss.”
“It’s definitely one of those can’t-miss intervals. It’s just like that
magical feeling on those rare days out there playing. Playing out of
your head, de-Lint calls it. Loach calls it The Zone.”
David Foster Wallace, Infinite Jest
I
n this chapter Magnetic Resonance Imaging (MRI) is introduced from a
physical mathematical point of view. This introduction can be helpful
to the reader to understand how the MRI images are generated and why
different MRI scans look so different one to another. In fact MRI, oppo-
sitely to Computed Tomography (CT) is a multiparametric imaging system. Tuning
the parameters differently brings different images with different features, which can
be useful to detect different issues in the tissue.
2.1 What is MRI
Magnetic Resonance Imaging (MRI), elderly known as Nuclear Magnetic Resonance
(nMR1) is an in vivo medical imaging system that uses the resonance property of
1the n has been removed to underline the complete safety of this kind of exam.
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physical objects under properly designed magnetic fields to generate image represent-
ing the inside of the object [1, 2, 3, 4]. This exam is non-invasive and much secure
compared to the analog X-ray tomography. In fact the electromagnetic rays in use
have a maximum frequency of about 105Hz (which is in the order of radio waves),
which is much less than the X-ray frequency, about 1016Hz. A higher frequency means
a shorter wavelength, a greater energy and by consequence a greater mutagen power.
RMI is said to be “safe” as the probability of a genetic mutation of the RNA a cell is
low. To make more safe the using of X, γ and β rays the time of exposition has to be
reduced.
2.2 A Physical introduction
2.2.1 The spin
The nucleus of an atom has a property called spin. This means that an atom can be
considered as a spinning wheel. This property leads also to an electromagnetic effect:
each nucleus generates a small magnetic field. Thus nuclei can be thought as magnets
with North and South poles on the rotation axes of the nuclei.
For our purpose the nucleus of hydrogen (H) will be considered, because it has an odd
number of protons and so the magnetic moment is not null and also because it is very
common.
So a proton p has an intrinsic angular momentum Jp and a magnetic momentum µp .
There exists a direct proportion between these two quantities
µp = γp Jp
where γp is a constant called gyro-magnetic ratio and it is related to the kind of atom
in examination. For instance the hydrogen has a ratio equal to γH ∼= 2.68T−1s−1. To
be more precise the gyro-magnetic ratio depends on the chemical bound of the atom
γp = (1−σ)γ
where the constant σ ∈ [10−6,10−4] is called chemical shift.
Now if a stationary and uniform magnetic fieldB0 is turned on, the quantum me-
chanic expected value of the intrinsic angular momentumwill satisfy the law
d < Jp >
dt
=<µp >×B0
so, given the proportion obtained,
d <µp >
dt
= γ<µp >×B0.
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Since it is impossible to measure the momentum of every single atom, the (total)
magnetic momentumM , defined as
M =
∑
p
µp
can be measured instead. This allows to formulate the differential equation
M˙ = γM ×B0 (2.1)
which will be fundamental for our purposes. Even if the nuclei are under a quantum
N
S
Figure 2.1: A nucleus of hydrogen can be seen as a magnetic wheel.
effect, a classical approach will be more feasible and will not lead to great errors.
2.2.2 Magnetic fields and relaxation
In absence of an external magnetic field the nuclei arrange themselves randomly and
their momentumsmutually annul, soM = 0. Since the magnetic field of the Earth is
weak (from 2 to 7 ·10−5 T), a normal body has a magnetic momentumM ≈ 0.
Otherwise, if a stationary magnetic field is turned on along the z-axis
B0 = (0,0,B0),
the nuclei will show a sort of herd mentality. In fact their rotation axes arrange
themselves parallel to the axis z. Some of them align themselves with the same verse
ofB0 (low energy), and some others will take the opposite direction (high energy). As
will be described in the next section, the most part of the nuclei will arrange in a low
energy position.
A more accurate description of the motion reveals that the axes has a precession
along the direction of the external field at the same frequency ω0, called the Larmor
frequency, but with different phases.
The precession tends to the equilibrium (0,0,Meq ) exponentially, with a recovery time
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B0
Figure 2.2: Herd mentality of the nuclei under a magnetic field.
T1 (spin-lattice) along the axis z, and with a loss time T2 (spin-spin) along the plane
xy . These two times are different because of the different phase of the nuclei.
The parametersT1 andT2 depends from the chemical boundof theHydrogenmolecules,
then from the tissue.
The main issue is that the precession is not visible for the total momentum because
the convergence to the equilibrium is too fast.
2.2.3 Attempt for seeing the relaxation
The disposition of the nuclei in the verse of the magnetic field causes the precession
motion to be difficultly measurable. To make the precession visible the alignment
to the axis of the nuclei has to be tuned in some way. According to the Boltzmann
factor, the probability that a nucleus arranges himself along the z-axis is equal to the
negative exponential of the ratio betweenmagnetic and thermal energy,
P (Ei )= exp
(
−
Emagn
Etherm
)
= exp
(
−
γB0×
kbTK
)
where ×∼= 1.05 ·10−34 J s is the normalized Plank constant, kb ∼= 1.38 ·10
−23 JK−1 is the
Boltzmann constant and TK is the absolute temperature in Kelvin degrees.
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Let us calculate this value for a typical MRI experiment, B0 = 1T , T = 300K .
P (Ei )∼= exp
(
−
3 s−1T−1 ·1T ·10−34 J s
1 ·10−23 JK−1 ·3 ·102K
)
= exp
(
−10−13
)
from the first order Taylor approximation it follows
P (Ei )∼= 1−10
−13.
This means that only one atom over 1013 chooses a high energy position, and the
magnetic momentum tends quickly to the z-axis.
From the Boltzmann factor comes an idea to make more measurable the precession:
decreasing the room temperature or increasing the external magnetic field.
For having a visible change two parameters must change to values that are physically
unacceptable for an in vivo acquisition. In conclusion another way to make the
precession measurable has to be found.
2.2.4 RF pulse and resonance
To move down the magnetic momentum the engineers had to resort to a Radio-
frequency pulse (RF-pulse), a secondmagnetic fieldB1 of a minor intensity than the
static field and rotating along the plane xy at exactly the Larmor frequency ω0. In
this way a physical phenomenon will occur, themagnetic resonance. In fact a huge
number of nuclei will gain energy and themagnetic momentumM will separate from
the z-axis.
Moreover, with the RF field turned on the phase of the precession will align, while
when the RF field is turned off there will be “dephasing”.
2.3 A Toy-model: the Bloch equations
To see mathematically phenomenons described in the previous section, toy-model is
needed, a set of mathematical equations that describes the motion of the aggregate
magneticmomentumM = (Mx ,My ,Mz). So let us consider the equation (2.1The spinequation.2.2.1)
applied to an external fieldB and study the solution of this equation for several exter-
nal fields.
2.3.1 Static field
Let us consider the case that only the static field along the axis z is on,B = (0,0,B0). If
a relaxation term is added to describe the polarization appears along the axis z (T1),
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and the decay along the xy-plane (T2).
This leads to formulate the Bloch equation
M˙ = γM ×B−
(
Mx
T2
,
My
T2
,
Mz −Meq
T1
)
(Bloch-1)
rewriting this equation component-wise
M˙x = MyB0−
Mx
T2
M˙y = MxB0−
My
T2
M˙z = −
Mz−Meq
T1
(2.2)
The solution to this ODE is
Mx = e
−t/T2(Mx,0 cosω0t −My,0 sinω0t )
My = e
−t/T2(Mx,0 sinω0t +My,0 cosω0t )
Mz = Mz,0 e
−t/T1 +Meq (1−e−t/T1)
(2.3)
whereω0 =−γB0 is the Larmor frequency. This is clearly a precession along the z−axis
at the Larmor frequency, and the solution tends to the equilibrium (0,0,Meq ) in a
exponential way, so the precession is very hard to see experimentally.
2.3.2 RF pulse
Turning on a RF pulse, the magnetic field rotates with angular speedω in the plane xy ,
with equationsB = (B1 cosωt ,B1 sinωt ,B0). The relaxation terms are ignored, since
the RF-pulse is on, resulting
M˙ = γM ×B (2.4)
again, rewriting the equation element-by-element,
M˙x = γ
(
MyB0−MzB1 sinωt
)
M˙y = γ (MzB1 cosωt −MxB0)
M˙z = γ (MxB1 sinωt −MzB1 cosωt )
(2.5)
Now, for simplicity, the system will be studied in a reference frame rotating along the
axis z like the RF pulse. 
e1 = (cosωt , sinωt , 0)
e2 = (−sinωt , cosωt , 0)
e3 = (0, 0, 1)
(2.6)
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z = e3
x
y
e1
e2
Rωt
Figure 2.3: The rotating non-inertial frame {e1,e2,e3}
Considering the functions(
u(t )
v(t )
)
=Rωt
(
Mx(t )
My (t )
)
(2.7)
where Rωt is the matrix of rotation of angle ωt .
Substituting the functions (2.7RF pulseequation.2.3.7) in the system (2.5RF pulseequation.2.3.5)
it is possible to obtain 
u˙ =
(
γB0+ω
)
v
v˙ = −
(
γB0+ω
)
u+γB1Mz
M˙z = −γB1v
(2.8)
Now, if the angular speed of the RF pulse is exactly the Larmor frequency ω=ω0 =
−γB0 the system is simplified and a second version of Bloch equation can be obtained
u˙ = 0
v˙ = γB1Mz
M˙z = −γB1v
(Bloch-2)
This means that the system is affected by resonance, since the aggregate momentum
tends to move down from the equilibrium position. This result is known as Larmor
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Theorem. The solution of this equation is simple:

u = u0
v = v0 cosω1t −Mz,0 sinω1t
Mz = v0 sinω1t +Mz,0 cosω1t
(2.9)
where, as before ω1 =−γB1.
The motion in inertial reference frame is the composition of two circular uniform
b
b
e3
e2
e1
(u0, v0,Mz,0)
(u(t), v(t),Mz(t))
Rω1t
Figure 2.4: The solution of the second Bloch equation in the non-inertial reference frame.
motions in orthogonal directions, whichmeans that themotion in analysis is a uniform
helical motion over a sphere.
2.3.3 Gradient pulse
For reasons that soon will be clear, sometimes in addiction to the RF pulse gradient
pulse, another magnetic field along z it is also needed. This pulse has the form
BG = (0,0,Bg )= (0,0,G · x)
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where, for instance, G is a constant vector of R3. Now, considering a field B0+Bg
instead of B0, the Eq. (Bloch-2RF pulseAMS.18) becomes
u˙ = γBg v
v˙ = −γBg v +γB1Mz
M˙z = −γB1v
(2.10)
Since B1≪ B0,Bg , the term B1 is negligible and thus it is possible to write the third
Bloch equation: 
u˙ = γBg v
v˙ = −γBg v
M˙z = 0
(Bloch-3)
The solution to this ODE is similar to the previous
u = u0 cosωg t − v0 sinωg t
v = u0 sinωg t + v0 cosωg t
Mz = Mz,0
(2.11)
where, as one can guess, ωg =−γBg .
2.4 Pulse sequences
As can be seen from (2.9RF pulseequation.2.3.9), an RF pulse has the effect to flip the
vectorM from the axis z of an angle θ =ω1τ after a time τ. Thus the following pulses
can be applied:
• a general θ-pulse: τ= θ
ω1
• a π2 -pulse: τ1 =
π
2ω1
.
After this pulse the aggregate magnetic momentum is
M (τ1)= (u0,Mz,0,v0)
• a π-pulse: τ2 =
π
ω1
.
After this pulse the aggregate magnetic momentum is
M (τ2)= (u0,−v0,−Mz,0)
Playing with pulses gets more informations about the precession. The following
sequences are the most popular ones:
1. inversion recovery
2. saturation recovery
3. spin echo
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2.4.1 Inversion recovery
Inversion recovery: after applying a π-pulse, and a waiting time of τ, another π2 -pulse
is applied andM is measured. Waiting for the system to get back to the equilibrium
of (2.3Static fieldequation.2.3.3) and repeating several times and for several values of
τ results in an increase of the signal-to-noise ratio. This sequence is shorted as follows(
π−τ−
π
2
− AT − t∞
)
n
where AT stands for acquisition time, and t∞ is a long time needed to get back to the
equilibrium, usually t∞ ≈ 4T1.
From the third component of (2.3Static fieldequation.2.3.3) gives
Mz(τ)−Meq = (Mz,0−Meq )exp(−
τ
T1
).
This means that −1/T1 can be computed as the slöpe of log(Mz(τ)−Meq ).
2.4.2 Saturation recovery
Saturation recovery: This sequence is shorted as(π
2
−Hs−τ−
π
2
− AT −Hs
)
n
Where Hs is a pulse that destroys the homogeneity of the field B0. After a time τ the
magnetization is partially recovered, the pulse flips it on the xy-plane. Again, −1/T1 is
computed from the slöpe of log(Mz(τ)−Meq ).
2.4.3 Spin echo
This sequence is shorted as (π
2
−τ−π
)
n
After 2τ the amplitude of the transverse magnetization will be relaxed by a factor
exp(2τ/T2)
2.4.4 T2∗
T2∗ is the real time constant of loss in the xy-plane, because the fieldB0 is not really
homogeneous. The relation between T2 and T2∗ is quite simple:
1
T2∗
=
1
T2
+γ△B0
where△B0 is the maximum variance ofB0.
T2∗ can be used in alternative to T2 to obtain different images.
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2.5 K-space and reconstruction
2.5.1 FromBloch equations to imaging
The aim of reconstruction is to create a 2Dmap of the proton density ρ(x) on each
slice. For this purpose only the transverse component ofM is now considered,
M∗ =Mx + iMy
In a similar way, the signal received from the coils is
s = Sx + iSy
For Faraday’s law the magnetic field generated by the body induces an electromo-
tive force to the coils
S(t)=
d
dt
Φγ = k
d
dt
∫
γ
ρ(x)Mdx
with γ a single loop in the coil. Now, considering a tiny slice over the z-axis, the
previous formula becomes
s(t )= k1
d
dt
∫
γ′
ρ(z)M∗(z)dz
with z ∈C2.
Applying a π2 -pulse, then a gradient for the selection of a slice, gives
M∗ = exp
(
−
t
T2
+ iω0t + iωg t
)
and then
s(t )= k2exp
(
−
t
T2
+ iω0t
)∫
γ′
ρ(z)exp(iωg t )dz.
Remembering that ωg =−γBg =−γG ·x and setting
G =Gx + iGy
the equation becomes
s(t )= k3exp
(
−
t
T2
+ iω0t
)∫
γ′
ρ(z)exp(−i tγG ·z)dz (2.12)
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2.5.2 K-space
Looking at the Eq. (2.12From Bloch equations to imagingequation.2.5.12), it is possi-
ble to observe that the signal s(t ) can be seen as the 2D Fourier Transform of k(t )
s(t )∝F2[ρ](k(t ))
where of course k(t )=− tγ2πG .
So, storing the values of s(t )
k3 exp
(
− tT2
+iω0t
) in a matrix called K-space and applying the
2-D IFFT algorithm the slice image is finally reconstructed.
Figure 2.5: An example of K-space and reconstructed image.
Figure 2.6: A phantom to obtain a simulated K-space.
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2.6 TR and TE Parameters
MRI is amulti-parametric imaging system: in fact you can play with some parameters
to obtain different contrast between the tissues.
Some of these parameters will be introduced in this section.
2.6.1 TR
Repetition Time (TR) is the time interval between the application of a pulse and
another.
After TR the longitudinal magnetization of the vectorM will be
Mz(t )=Meq
(
1−e−TR/T1
)
so each FID signal will be proportional to(
1−e−TR/T1
)
This means that the longitudinal magnetization will not reachMeq unless a TR≫ 4T 1
is set.
2.6.2 TE
TE stands for echo delay time (or time to echo). Instead of making the measurement
immediately after the RF pulse (which is impossible in pratice), waiting a short amount
of time and thenmaking the measurement will be a better solution.
2.7 Sequences
As stated previously, different images can be acquired fromMRI by tuning differently
the sequence parameters. Below some of most common MRI sequences and their
utility in detecting different features are introduced and explained.
2.7.1 T1-weighted
T1-weighted images are obtained using a short TR. Useful in scanning the human
brain to see contrast between gray and white matter, 3D T1 images are mostly used for
brain tissue segmentation and parcellation since they reveal most of the anatomical
informations about the brain.
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Chapter 3
Positron Emission Tomography
Fenton here was a dyed-in-the-wool paranoid schizophrenic who
believed that radioactive fluids were invading his skull and that
hugely complex high-tech-type machines had been specially de-
signed and programmed to pursue him without cease [...]. With the
aid of cutting-edge Positron-Emission Topography or ’P.E.T.’ tech-
nology [...], they could scan and study how different parts of poor
old Fenton’s dysfunctional brain emitted positrons in a whole differ-
ent topography than your average hale and hearty nondelusional
God-fearing Alber-tan’s brain, advancing science by injecting test-
subject Fenton here with a special blood-brain-barrier-penetrating
radioactive dye and then sticking him in the rotating body-sized
receptacle of a P.E.T. Scanner
David Foster Wallace, Infinite Jest
P
ositron Emission Tomography shall be introduced in this Chapter, along
with some notion of tracer kinetics which will guide the reader to learn
about the Sokoloff model and the Patlak plot method. These methods are
used for computing the absolute rate of glucose metabolism (aMRGlu.)
which will be treated in the next chapters.
3.1 General introduction
3.1.1 What is PET
Positron emission tomography (PET) is a nuclear medical imaging technique that
produces an image of functional processes in the body. The PETmachine detects pairs
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of gamma rays, or positrons emitted by the annihilation of a tracer (as the 18FdG),
introduced into the body [2, 5, 8].
b
b
Figure 3.1: Scheme of acquisition for the PET imaging system.
The particularity of PET stands in the possibility to recovering a sequence of
images as a time series. This allows the researchers to study the evolution of the tracer
kinetics.
Since the positrons are emitted two by two, before considering a couple of data as
the product of the same annihilation process, the machine filters only the pairs of
positrons incoming in the same (small) temporal window△t . This allows to reduce
the effect of scattering, so the data collected after this filtering is quiet reliable.
3.1.2 Mathematical modeling
The mathematical models for the PET scan will be briefly introduced.
This is the Radon transform used in Computed Tomography (CT)[5, 7]
R f (t ,θ)=
∫
ℓt ,θ
f (x¯)dx¯
where f is the image to reconstruct and R f (t ,θ) its projections on the plane of
acquisition. It is possible to recover the image f , for instance by using the inverse of
the Radon transform, the filtered backprojection formula
f =
1
2
R
∗
[
F
−1(|ν|F (R f ))
]
(3.1)
where F is the Fourier Transform and R∗ is the Backprojection Operator, defined as
R
∗g (x, y)=
1
|S1|
∫
S1
g (x¯ · θ¯,θ) dθ.
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In case of functional tomography as PET or SPECT, the attenuated Radon transform
is used
Ra f (t ,θ)=
∫
ℓt ,θ
exp(−Da(x¯)) f (x¯)dx¯
where the divergent beam transform is defined as
Da(x¯)=
∫
ℓ+
t ,θ(x¯)
a(y¯)d y¯ =
∫+∞
0
a(x+ sθ) ds .
In this notation a(x¯) is a map of attenuation, obtained by an aligned CT (or MRI-
obtained pseudoCT image), or estimated for the target zone of the body (as brain,
thorax, legs).
In PET case the coils receive two signals in the opposite direction ℓ+ and ℓ−,
belonging to the same line ℓ. So in that case the integral of a does not depend on x¯,
and then the attenuated Radon transform Equation can be rewritten as
R˜a f (t ,θ)= exp(−Ra(t ,θ))R f (t ,θ)
This fact allows to correct the attenuation with ease in case the attenuation map a is
known.
Reconstruction can be made simply using filtered backprojection formula after cor-
recting for attenuation with simple multiplication by a factor exp(−Ra(t ,θ)).
3.2 Kinetics of the Tracer in PET
In case PET images are axtracted as a temporal sequence of images (or in list-mode)
it is possible to use them as measures for the identification of a model [2, 3, 4]. This
identification can bring information about the whole process.
3.2.1 What are compartmentmodels
A compartment model is a type of mathematical model used for describing how
materials or energies are transmitted among the compartments of a system. Each
compartment is assumed to be a homogeneous entity. Hence a compartment rep-
resents, in medical application, a group of organs exchanging material at the same
speed one with another.
The kinetics of thematerial is described by an ordinary differential equations system
with, as unknown functions, the concentration of the considered material in each
compartment.
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Q1
P1
C1 = Q1/V
K01
u = Dδ(t)
Figure 3.3: An example of compartment model.
j-th compartment at a speed F j i (Qi ), where the function F j i can be eventually linear.
It is possible to measure the concentration in some compartments. If this measure is
missing, it is considered as zero.
3.2.4 Tracers
A tracer is a small quantity of substance used for the purpose of tracking a specific
molecule called traced.
The tracer:
1. can be measured independently from the traced
2. follows the dynamics of the traced and do not perturb the state of the system
(small quantity)
3. is kinetically indistinguishable from the traced
3.2.5 Indistinguishability principle
From the third assumption comes out the following principle:
P (a particle leaving j is tracer)= P (a particle in j is tracer).
This means that
fi j
Fi j + fi j
=
q j
Q j +q j
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or equivalently
Fi j
Q j
=
fi j
q j
= ki j (Q).
qi
c1 = q1/V
f0i
ui
fij
fji
Figure 3.4: A general model for tracer kinetics. Only one of the n compartments is shown for
shake of simplicity.
The general model for the kinetics of the tracer can be written as follows:
q˙i =
∑
j 6=i
fi j (Q,q)−
∑
j 6=i
f j i (Q,q)+ui (t ) , qi (0)= qi0
ci =
qi (t )
Vi
or ci = 0
If all the functions ki j (Q)= ki j are supposed constant then fi j (Q)= ki jq j . In this
case the model becomes linear:
q˙i =
∑
j 6=i
ki jq j −
∑
j 6=i
k j iqi +ui (t ) , qi (0)= qi0
ci =
qi (t )
Vi
or ci = 0
3.2.6 Amore general view
Under the hypothesis of linearity the model goes under the category of Linear Time-
Invariant model and can be written in state-space form LTI state-space [2]{
x˙ = Ax+Bu , x(0)= x0
y = Cx
where u is the input, y the output and the system is determined by (A,B ,C ).
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Theorem 3.2.1. The system (A,B ,C ) is equivalent to the direct input-output relation
y(t )=Cx(t )= (C exp(t A)B)∗u(t )
Proof Considering xˆ, the Fourier transform of x,
sxˆ = Axˆ+Buˆ
which is equivalent to
xˆ = (sI − A)−1 Buˆ.
and finally
yˆ =C xˆ =C (sI − A)−1 B
that leads to the thesis.
By effect of Theorem 3.2.1theorem.3.2.1 the impulse response function (IRF) can
be defined for such equations.
Definition 1. Given the LTI system (A,B ,C ), its IRF is the function
φ(t )=C exp(t A)B
and its Fourier transform, the Transfer Function
φˆ(s)=C (sI − A)−1 B
so that y =φ∗u and yˆ = φˆuˆ.
Lemma 3.2.2. Under the hypothesis the the input is a bolo,
u(t )=Dδ(t )
, the Equation
y(t )=φ(t )∗u(t )=
becomes
y(t )=φ(t )∗Dδ(t )=Dφ(t ).
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1u(t)
2
3
c(t)
Figure 3.5: Is this model identifiable?
3.2.7 Identifiability and identification
Definition 2. The model (A,B ,C ){
x˙ = Ax+Bu , x(0)= x0
y = Cx
is (uniquely) identifiable if it is possible to determine (uniquely) the nonnegative en-
tries of A, given B ,C, and the exact data x0, y,u.
Observing the model in Fig.3.5Is this model identifiable?figure.caption.31, the
reader wanders whether this model is identifiable or not. Next definitions and theo-
rems will be helpful to solve many identifiability problems.
Definition 3. 1. A Compartment k is in/out-put reachable if ∃ a path from an
in-out-put compartment to k.
2. A system (A,B ,C ) is in/out-put reachable if every compartment is in/out-put
reachable.
For instance, the system of Fig.3.5Is this model identifiable?figure.caption.31 is
input reachable but not output reachable. Next theorems will link such property to
identifiability.
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3.2.8 Necessary and sufficient conditions
Theorem 3.2.3. (Necessary conditions): Let (A,B ,C ) be an identifiable system, then:
1. The system is input reachable
2. Every compartment with an outgoing path is output reachable
Again, taking the system of Fig.3.5Is this model identifiable?figure.caption.31,
his reachability cannot be excluded or proved. Some other theorems are needed to
achieve this goal.
Observation: The transfer function φˆ(s) is a rational function of the form
φˆ(s)=
N (s)
D(s)
with N ∈P n−1,D ∈P n
where n = dim(A).
In fact
φˆ(s)=C (sI − A)−1 B =C
ad j (sI − A)
det (sI − A)
B
and ad j (A)=
n−1∑
k=0
Rk s
k
Theorem 3.2.4 (Sufficient conditions 1). In case the equations of the numerator and
denominator have a (unique) solution, then the system (A,B ,C ) is (uniquely) identifi-
able.
Theorem 3.2.5 (Sufficient conditions 2). If the equations φ(k)(0) = CAkB , fork =
0, . . . ,n−1 have a (unique) solution and the denominator is never null, then the system
(A,B ,C ) is (uniquely) identifiable.
The system of Fig.3.5Is this model identifiable?figure.caption.31 can be written as
A =
 0 k1 k30 −(k1+k2) 0
0 k2 0
 ,
B = (0,1,0),C = (0,0,1/V3)
and so by the theorems above it is finally possible to reach a conclusion: this model is
identifiable, but not uniquely.
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3.2.9 Identification
Identification can be made using the results of the two sufficient conditions, but such
techniques have revealed to be numerically inaccurate. So the calculation of the
parameters is given by a (weighted) nonlinear least squares method.
A = argmin ||y − yA||
2 = ||y −φA ∗u||
2 =
= ||y − (C exp(t A)B)∗u||2
Of course nonlinear fitting using the original differential equations can be most of the
times a reliable alternative.
3.2.10 Sokoloff Model
The Sokoloff model (1970s) is themainmodel studying the kinetics of the tracer 18FdG
in the brain. It uses a time sequence of PET images as measure and the injected tracer
activity as input. Once fitted, the model provides the absolute glucose rate of that
particular region of interest.
Cp
C = VbCp + (1− Vb)[Cf + Cf b]
u(t)
Cf Cb
k3k1
k2
Figure 3.6: Sokoloff compartment model
This model is also known as 3K, as it is a three-compartment model with the
hypothesis that the third compartment is irreversible. As the model has a unique data
input, a (eventually PET-based) measure of the plasma glucose is needed for fitting
this model. The model is the following, in LIT form
A =
 −k1 k2 0k1 −(k2+k3) 0
0 k3 0
 (3.2)
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Volume Of Interest (VOI)C (t ) are sufficient for the identification of the Sokoloff model.
An easier and fastest way to identify the model is to use the relation
C (t )=K
∫t
0
Cp(τ)dτ+VbCp(t ) (3.3)
Rewriting Equation 3.3Patlak fit methodequation.3.2.3 brings to light a linear depen-
dence, in fact
C (t )
Cp(t )
=K
∫t
0 Cp(τ)dτ
Cp(t )
+Vb (3.4)
Hence, it is possible to compute K with linear fitting using least-squares methods.
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Chapter 4
Most common algorithms for
Neuroimaging
S’accende il verde, innesto la marcia imballando il motore, sterzo
tutto con la sinistra e nello stesso tempo alzo la destra al finestrino
e sparo. L’uomo che inseguivo si piega sul volante. L’uomo che
m’inseguiva abbassa la pistola ormai inutile. Io ho imboccato già
la via trasversale. Non è cambiato assolutamente nulla: la colonna
si muove con piccoli spostamenti discontinui, io sono sempre pri-
gioniero del sistema generale delle macchine in marcia, in cui non
si distinguono gli inseguitori e gli inseguiti.
Italo Calvino, Ti con Zero
F
or computing the biomarkers from the images it is necessary to study, test
and (whenever possible) improve many algorithms. From the accuracy
of such algorithm it depends the order of bias and therefore the reliability
of the results. Some of the useful and widespread algorithms used in MRI,
PET and PET/MRI Neuroimaging pipelines will be treated in this chapter.
The chapter is organized as follows: in the First Section, some formal definitions
will be given. The Second Section contains an introduction to Registration (or co-
registration) algorithms, useful to align images one to another also from different
sources. In the Third and Fourth Sections, Segmentation/Parcellation and Cortical
Thickness evaluation algorithms will presented. Such algorithms are tuned mostly for
MRI, but could be applied to PET if needed. Sections 5 and 6 contains methods used
in PET and PET/MRI imaging. Section 7 contains a pipeline for PET/MRI studies that
will be applied in the last Chapters.
All the most used programs for Neuroimaging have at least some Registration and
Segmentation routines, many of them have also Cortical Thickness evaluation. It is
less common to find a PET Kinetic Modeling, because it is a specific PET application.
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4.1 A formal introduction
For a more precise description of the algorithm in use we shall introduce somemathe-
matical definitions of the objects that will be used in the next Sections.
Definition 4. An image can be considered as a function, say
I :Ω⊂Rd −→R
with the dimension d usually set to 2,3 or 4, sampled over a grid of points
X =
{
x1, . . .xp
}
s.t. xi ∈Ω
An image can be represented as a vector (with a slight abuse of notation)
I = (I (xi ))i=1,...,n
Note that the points in X can be eventually equispaced. If d = 3, X can be written
in matrix 3D form
Xi , j ,k =
[
xi , j ,k
]
s.t. xi , j ,k ∈Ω ∀i/ j/k = 1, . . .N/J/K .
In that case the image is stored in form of a 3D N × J ×K matrix
Ii , j ,k =
[
I (xi , j ,k)
]
Definition 5. A segmentation or VolumeOf Interest (VOI) is an arbitrary subset of the
domain Γ⊆Ω and itsmask is a function
γ(x)=
{
1 x ∈ Γ
0 x ∉ Γ
It can be represented as a binary (3D/d-D) image, sampled at the same points X of a
reference image I .
In Neuroimaging pratice, a VOI can tell where a given functional or morphological
structure is. Of course, the human brain is made up by lots of VOIs, so another
definition is needed. Given a VOI it is possible to measure some important features as
the Volume of the VOI itself, given by the sum of the voxel times the voxel volume, or
the mean1 intensity of a co-sampled image.
1or standard deviation, or other statistical features.
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Definition 6. AnAtlas (or deterministic Atlas) is obtained froma set of non-overlapping
VOIs
Γ1, . . . ,Γn s.t. Γi ∩Γ j =; ∀i 6= j
An atlas can be represented as a function
A (x)=
{
i if x ∈ Γi
0 otherwise
or equivalently (if d = 3) as a 3D image, sampled at the same points X of a reference 3D
image I .
Another equivalent representation of an atlas is as a four-dimentional matrix N × J ×
K ×n, consisting in merged 3D binary representation of the VOIs.
In some situation the brain structures are detected from previous observation,
thus given as a probability measure.
Definition 7. A Probability Map is a set of functions mapping the domainΩ to the set
[0,1]
P =
{
P1, . . . ,Pn :Ω−→ [0,1] s.t.
n∑
i=1
Pi ≤ 1
}
It can be represented (in d = 3 case) as a 4D image matrix N × J ×K ×n, consisting in
merged 3D image representation of the functions.
Note that an Atlas can be seen as a particular case of Probability Map. A Probabilis-
tic Atlas can be transformed to a regular, deterministic Atlas by applying themaximum
probability criterium
A (x)= arg max
i=1,...,n
P˜i (x) (4.1)
with P˜i (x) defined as
P˜i (x)=
{
Pi (x) if Pi (x)>= t
0 if Pi (x)< t
for a given threshold t ∈ [0,1] and for each Pi ∈P .
4.2 Registration
Registration of twomedical images is a basic, fundamental algorithm inNeuroimaging.
Suppose to have two images of the same subject acquired in two different sessions [4,
6, 7, 8]. The subject has possibly moved between sessions, so in order to catch the
differences between the two scans an operation on the images is needed.
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A rigid registration is used when dealing with the same subject, assuming his head
shape has not changed much between the two sessions. An affinity, or in some case a
diffeomorphism, is used to put different subjects in the same space.
Also the distance can be different according to the needs. Some examples:
• SSD, sum squared differences
SSD [A,B ]= 1/2
∫
Ω
(A(x)−B(x))2 dx
• NCC, normalized cross-correlation
NCC [A,B ]= 1−
〈A,B〉2
||A||2||B ||2
with the scalar product
〈A,B〉 =
∫
Ω
A(x)B(x) dx
• NGF, normalized gradient-field
NGF [A,B ]=
∫
Ω
1−〈gη(A),gη(B)〉
2 dx
where the gradient-field is defined as
gη(A(x))=
▽A(x)√
||▽ A(x)||2+η
In practice NCC is used when registering the same subject with the same system (same
MRI sequence, PET), since we can assume that the numerical values of the images did
not change too much. In registering different MRI sequences NCC is a better option,
while when registering two different modalities2 NCC and NGF are equally reliable
measures.
Since the registration process is an iterative algorithm, in some case registration
programs can fail if the two images are too different in orientation. In Neuroimaging
practice, this problem occurs in about 1/100 cases and it is solved by rotat ing and
translating manually the input image to make it closer to reference.
A good trick for improving the speed of registration is to apply the registration algo-
rithm to progressively undersampled versions of the image, obtained by averaging
voxels squares3 [6]. In this way the registration is progressively refined from a raw
image (quicker to register) to the original one.
2e.g. registering a PET to a MRI image.
3e.g. 4×4×4 voxels, 3×3×3, 2×2×2
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4.3.1 How to quantify the goodness of a segmentation
Manually segmented atlases are commonly considered as the gold standard. So, in
order to quantify the error between a manually segmented VOI and one obtained
automatically somemeasures have been defined.
Definition 10. Given two VOIs A and B, expressed in form of set containing the 1-
valued voxels, it is possible to define:
the dice coefficient or Soreson Coefficient
Qs =
2|A∩B |
|A|+ |B |
the Jaccard index
J =
|A∩B |
|A∪B |
with |·| the cardinality of the set, equivalent to the sum of the values of the VOI inmatrix
form.
Both indexes take values in [0,1]. Interestingly, the relation between the two can
be proved to be Qs ≥ J and Qs = J if and only if both are 0 or 1. This means that in
practice Jaccard index is more severe about small differences between VOIs.
4.3.2 Pre-segmentation CorrectionMethods
Before applying segmentation algorithm it is a good practice to apply some correction
algorithms, in order to reduce segmentation errors.
First of all in brain MRI, it is necessary to correct the bias due to inhomogeneity of
the field B0, which in practice is not completely stationary. Most used algorithms are
called N3 and N4[9] Bias Field Correction. Another approach suggests to measure the
field with the MRI directly.
Another common useful operation is to find a brain tissue mask in order to isolate the
brain tissue from the surrounding meninges, dura mater, bones, eyes and other tissue.
This operation is referred as skull-stripping.
In some neurological illness as MS, T1-hypointense lesions appear in the brain, af-
fecting the segmentation quality. The correction most in use is called lesion filling[2].
This approach proposes to inpaint WM lesion putting inside the lesion mask intensity
values more similar to the surrounding Normal Appearing WM (NAWM). It has been
proven that the segmentation obtained after fiilibg has improved dice and Jaccard
coefficient when comparing to manual segmentation.
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• φ(x,0)= x
• the thickness is contrained,
∣∣φ(x,1)−φ(x,0)∣∣< τ for each x ∈GW I
• there exists a velocity fieldΩ× [0,1]−→R3 such that
dφ
dt
= v(φ(x, t ), t )
or equivalently
φ(x, t )= x+
∫t
0
v(φ(x, t ), t ) dt
This function φ is meant to be a continuous map between theGW I and the exterior
of the cortex. The idea of this approach is not to explicitly give the exterior of the
cortex in order to compute a correct value even in presence of segmentation error
between the cortex and the dura. On this purpose it is necessary to give a condition∣∣φ(x,1)−φ(x,0)∣∣< τwhere τ usually set to 4 or 5 is the maximum value of the cortical
thickness.
Equivalently, the diffeomorphism φminimizes the functional
E(φ(x,1))=
∫1
0
||v(x, t )||2 dt +
∣∣∣∣Pw (φ(x,1))−Pwg (x)∣∣∣∣2
subject to:
φ(x, t )= x+
∫t
0
v(φ(x, t ), t ) dt
T (x)=
∣∣φ(x,1)−φ(x,0)∣∣< τ ∀x ∈GW I
At this point the optimal solution φ is computed with an iterative scheme, and the
function T (x) is the measure of the thickness of the cortex, as wanted.
4.5 Motion Correction and Partial Volume Correction
This Section concerns some algorithms used in PET for correcting some issues linked
to the nature of the PET system.
First of all motion. List-mode PET4 can last up to 30 minutes, and the patient happens
to move a little in this time. In order to reduce this source of bias, Motion Correction
is applied.
4or PET time series, resulting in a 4D image, made up by 3D PET images called frames.
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PET or from amean image of 4D list-mode PET. SUV is defined as
SUV (VOI )=
SUV (VOI )
Cin j
the mean value in the VOI divided by the injected tracer activity. In case the injected
activity is unknown, it is possible to compute the SUV Ratio (SUVR) as
SUV R(VOI )=
SUV (VOI )
SUV (Re f )
=
mean(PET (VOI ))
mean(PET (Re f ))
with Re f a reference VOI, usually the whole brain VOI, or an area that is proved not to
be involved by the illness6.
The second way is to validate a kinetic model for the specific PET tracer in use7.
Once amodel is validated, fitting themodel data (as explained in Chapter 3) outcomes
the parameters value. From such parameters it ipossible to compute many biomark-
ers.
Of course it would be better to give a physicalmeaning to the biomarkers in order to
give the clinician results to be read and interpreted correctly.
4.7 A faster computation for pixelwise Patlak
As stated in previous Chapter, the commonly adopted model in the case of tracer
18Fdg is Sokoloff model and a simple way to obtain the absolute glucose rate aMRGlu
is the Patlak linear fit.
As seen in Chapter 3, the absolute metabolic rate aMRGlu is proportional to the
coefficient K , which can be recovered by fitting
C (t )
Cp(t )
=K
∫t
0 Cp(τ)dτ
Cp(t )
+Vb (4.2)
6In most cases, it can be the cerebellum cortex/WM or in some case the WM.
7this requires several subject scans as training data.
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can be solved with ease; the solution is
K =
nX ·Y T − sum(X)sum(Y )
nX ·XT − sum(X)sum(X)
Vb =
sum(X)
n
−K
sum(Y )
n
.
It is also possible to compute the standard deviation for the slope K
SD =
√√√√√ 1
n−2
(
Y − Y˜
)
·
(
Y − Y˜
)T(
X − sum(X)
n
)
·
(
X − sum(X)
n
)T
where Y˜ is the vector of estimated values
Y˜ =KX +Vb .
In case the pixel-wise image is going to be computated, it is computationally
inefficient to compute the value of K for each voxel singularly. The number of voxels
in a 3d image can be of the order of 106. A faster way can be to store all the values of
the vectorsX in a matrix, which will be called with a slight abuse of notationX , and
compute the vector K using the same solution as before. Parallel calculus for matrix
multiplication, already implemented in several programming languages, will speed
up the computing time.
4.8 Pipelining
A pipeline is a sequence of operation to be applied to every subject’s images in order
to obtain the desired biomarkers. In this section a sample study shall be presented.
Suppose to have a dataset of at least 30MS patient, all undergoingMRIwith sequences:
T1, FLAIR and DIR. The goal of the study is to obtain volume values for WM and GM
lesions for each VOI in amorphological atlas, obtained by segmenting T1 usingmanual
segmentation or, more easily, a fully automated software as freesurfer.
Even if this task seems easy, many operations are needed in order to obtain the
requested measures with minimal bias. First of all, T1 has to be corrected for Bias-
Field and Lesion-Filling, before segmentation. Furthermore, all lesion masks and
anatomical atlas have to lie in the same space. For simplicity, an usual choice could
be to move FLAIR and DIR in T1 space before manual segmentation.
Once we have the atlas from T1 and the WM lesion and GM lesion masks, it is easy to
compute the volume of WML and GML in each VOI of the atlas by
Vol (Mask,VOI )= dV |Mask∩VOI |
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where | · | is the number of the voxel in the intersection and dV is the Volume (say in
mm3) of a single voxel, which can be easily found in the image metadata.
Fig 4.7The flowchart of this sample MS pipeline. Squares represent the images, Circles
the operations, Trapezoids masks and atlases, Double squares with rounded corner
the numerical results.figure.caption.43 contains a graphical representation of the
sample pipeline presented above.
T1 FLAIR DIR
Bias Field
Correction
Rigid Reg-
istration
Rigid Reg-
istration
BF-Corrected T1 FLAIR to T1 DIR to T1
WM Lesion
Filling
Manual
Segmentation
Manual
Segmentation
Corrected T1 WML mask GML mask
Anatomical
Segmentation
Compute
Les. Vol. in
each VOI
Compute
Les. Vol. in
each VOI
Atlas
WML Volume GML Volume
Figure 4.7: The flowchart of this sample MS pipeline. Squares represent the images, Circles the
operations, Trapezoids masks and atlases, Double squares with rounded corner the numerical
results.
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Chapter 5
AMS study in PET/MRI
“Incominciamo male!” ho pensato davanti al medico legale della
Asl di via Luzzatti. Ero davanti a lui perché doveva autorizzare il
rilascio per il mio permesso invalidi. Questo signore, molto pre-
sumibilmente laureato, dopo avermi visitato e aver visionato i 750
certificati che sanzionavano inesorabilmente la mia sclerosi multi-
pla galoppante, con fare professionale ha decretato: “Lo autorizzo
per due anni, poi vedremo come procede”.
Fiamma Satta,Diario
T
he ongoing of Multiple Sclerosis inMRI and other imaging techniques have
been studied under several points of view, but (at present date) no pub-
lished research included brain metabolism yet. PET glucose tracer 18Fdg
allows the computation of the absolute Metabolic Glucose Rate (aMRGlu),
which is a good biomarker indicating the brain activity. In this chapter a pilot study
with PET/MRI involving 31 patients is presented.
5.1 Introduction
The relationship between inflammatory processes and atrophy inMS is still unraveled,
and studying the metabolism could offer an important, missing ring of this chain.
Microglial activation in the early phases of MSmay lead to several metabolic effects on
synapses and neurons, causing a progressive neuronal loss and GM atrophy, inducing
metabolic changes in the cortex in a first phase and then determining synapsis and
neuronal loss and atrophy.
Under this hypothesis, it could be possible to prove the presence of changes in cortical
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metabolism before atrophy. Longitudinal studies [5, 4] lead on AD seem to confirm
this idea.
5.2 Materials andMethods
5.2.1 Patients
Two groups of MS patients were enrolled in the study:
• 14 CIS suggestive of MS (7 patients) or early RRMS (eRRMS, 7 patients) with
short disease duration (DD 1.7±0.33) and no sign of cognitive impairment.
• 15 RRMS with a longer DD (19.1±10.0) and clear signs of cognitive impairment.
In order to avoid age-related biases, the age of the two groups was selected in the range
between 22 and 57 years. No significant difference of age was found between these
two groups. The study was approved by the local Ethics Committee that, however, did
not give the permission of enrolling normal controls in the study. All patients gave
written informed consent.
5.2.2 MRI and PET
The following MRI images of every patient were acquired on a PET/MRI 3T Siemens
System (BiographmMR PET Siemens)
• T2 coronal thoracic short tau inversion recovery space (STIR) for Aorta segmen-
tation.
• 3D T1MPRAGE of the brain for brain segmentation and parcellation.
• 3D brain FLAIR for WML detection.
• 3D brain DIR for GML detection.
To the PET side, an injection of 18Fdg glucose tracer was injected in each patient. After
the injection the PET was acquired in thorax and brain in three different sessions:
early thorax (TOR1), late thorax (TOR2) and late brain (BRAIN2).
This subdivision was made in order to accurately estimate the plasma glucose from
the aorta VOI in TOR1 and TOR2 images and to let the patient rest a while between
the early and late acquisition.
The choice of recovering the input function C (t) from the aortic tract is slightly
different from the usually-adopted strategies: usually the input function is derived
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either by arterial sampling, which is the golden standard but it is also very invasive,
or by carotid/brain vessels PET images. This last option is the most used, since the
carotid/brain vessel signal comes for free with the brain PET. However, such signal
might be very poor because of the Partial Volume Effect. This is not such a big problem
for aortic tract, since there is no surrounding body with such high tracer signal.
Even if the aorta-approach has proven in our environment to be consistent with
arterial sampling, it has not been proven yet to obtain better results than the carotid-
approach.
5.2.3 Pipeline
The purpose of this study is to obtain absolute Metabolic Rate of Glucose (aMRGlu)
and Cortical Thickness (CTh) values for the cortical parcels of DTK atlas, extracted
with freesurfer. To approximate the plasma glucoseCp(t ) it has been chosen to obtain
PET/MRI images of the thorax right after the injection (TOR 1) and after 30 min (TOR
2), in order to recoverCp from the Aortic VOI. After TOR2, the scanner moves to the
head to acquire (Brain).
Now, assuming that each PET is aligned to the relativeMRI, the best way for registering
PET TOR1 to PET TOR2 is to align the two relative MRIs and apply the transformation
to PET. Once the Aorta VOI is manually segmented, it is easy to get an aortic Time
Activity Curve (TAC) by averaging the two PET inside the Aorta VOI.
For what concerns the anatomy, MRI is rigidly registered to a template so that the
bicommissural line is horizontal in Sagittal view and the real size of a voxel is 1mm
per size. This orientation will be referred as BIC space. PET Brain is also aligned to
BIC using the same transformation as its MRI, thenmotion correction and PVC are
applied.
The T1MRI sequence is processed using Freesurfer and the resulting atlas is registered
to the BIC space. Freesurfer also provides an estimation of CTh for all the cortical
parcels of the atlas. After having obtained the TAC C (t) for each VOI of the atlas by
averaging, it is necessary to interpolateCp(t ) to the same timepoints of the brain.
At last, Patlak fit method is applied to obtain aMRGlu value for each VOI of the atlas.
In Fig 5.1The sample flowchart of the PET/MRI pipeline discussed.figure.caption.45 it
is possible to see a flowchart representation of the pipeline. Patlak fit method was also
applied voxel-wise resulting in aMRGlu parametric images.
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areas.
5.2.4 Statistics
When comparing two groups, their normality was checked using Shapiro-Wilk test and
homoscedasticity using F-test. Then, the two groups were compared using unpaired
t-test andMann-Withney test. In case of multiple comparisons, False Discovery Rate
(FDR) method has been used to correct p-values. Linear correlation was computed
using Spearman’s rho value. Significance level is set to 0.05.
5.3 Results
5.3.1 Differences between CIS/eRRMS and RRMS
The two clinical groups have show a few differences in Cortical Thickness: 5/33 left,
9/33 right cortical areas and 3/10 Lobes resulted significantly different; none of these
differences survived FDR correction.
To the other side, aMRGlu differed in 13/33 L, 20/33 R areas and 11/14 lobes after
correction. Lesion load was found significantly different in 4/33 L, 6/33 R and 6/14
Lobes for Lesion Number and 6/33 L, 4/33 R, 6/14 Lobes for Lesion Volume.
5.3.2 Grouping for lesion number
In order to better delineate differences, a second grouping criteria was added, selecting
CIS/eRRMS with less than 70 WM+GM lesions and RRMS with more than 70 lesions.
Resulting groups were made of 11 and 12 patient each.
Cortical thickness was found significantly different in 14(5 after correction)/33 Left
VOIs, 15(5) Right and 5(1)/10 Lobes.
Absolute Glucose Rate differed in 21(10)/33 L, 28(12)/33 R and 13(8)/14 Lobes.
5.3.3 Correlations
Correlations were analyzed for Lobes, adding the Left and Right WM for noncortical
measurements (all, excluded Cortical Thickness).
No significative correlation was found between Cth and aMRGlu in the cortical Lobes.
To the other side, L WM aMRGlu. , inversely correlated with R and L Temporal and
Insular Cth and RWM aMRGlu inversely correlated with the Cth of R Insular Lobe.
As concerns the relationship between Cth and Lesion Load, it was possible to find
inverse correlations in L Frontal and Parietal Lobes and R Parietal and Temporal, both
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5.4 Discussion
The few significative differences between CIS/eRRMS and RRMS in CTh seems to
be in countertrend with the findings of MS literature. However this result can be
derived from our low sample number, which could not be sufficiently large to detect
differences in CTh[10]. Somemore significative differences have been found exclud-
ing some CIS/eRRMS with much lesions and some RRMS patients with lower lesion
number.
From this cohort’s results it is possible to hypothesize that aMRGlu may have an ear-
lier change than atrophy (CTh) and focal lesion appearance, as aMRGlu differences
between groups were significative in more areas. This result has to be checked with
stronger data, as a longitudinal study.
The inverse correlations between aMRGlu and lesion load suggest that themetabolism
of the brain is dependent to the inflammatory process, but differently from Cth. In-
deed, the results given by voxelwise analysis, together with the absence of correla-
tions between CTh and aMRglu, are suggestive of a non-linear relationship between
metabolism, inflammation and neurodegeneration. The cortex of MS in early disease
phases may go through different states of metabolic activity.
It is possible to formulate this hypothetical model, to be verified in further study:
1. In a first phase, pro-inflammatory cytokines released by activated microglia[6,
16, 17] lead to an increase of the synaptic metabolic rate.
2. In a second phase, the excitotoxic damage[3, 18, 19, 20] determines a progressive
decrease in synaptic activity with a consequent decrease of metabolism, but still
normal CTh.
3. Finally, in a third phase, the progressive loss of synapsis and the neuronal death
determine the appearance of cortical atrophy.
It should be pointed out that all these conditions may take place in different areas at
the same time. Hence only an accurate voxel-wise analysis can validate or reject such
model.
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Chapter 6
Amyloid PET/MRI analysis for AD
One tended to speak of him, instinctively, as a spiritual casualty,
a lost soul: was it possible that he had really been desouled by a
disease?
“Do you think he has a soul?” I once asked the Sisters. They were
outraged by my question, but could see why I asked it. “Watch
Jimmie in chapel”, they said, “and judge for yourself.”
Oliver Sacks, The ManWhoMistook His Wife For A Hat
A
lzheimer’s Disease (AD), introduced in the first Chapter, is characterized
by the excessive accumulation in the brain of beta-amyloid. Modern PET
tracers are able to detect, quantify and localize this phenomenon with
greater precision with respect to the analysis of Cerebrospinal Fluid CSF,
extracted with a Lumbar Puncture (LP).
In this chapter a new study for PET quantification will be presented. The contents
above are obtained with the collaboration of Department of Nuclear Medicine, Leipzig
University DE, and the relative paper is currently in submission for publication.
6.1 Introduction
Amyloid accumulation is common in normal aging brain, but reaches abnormal levels
in younger AD (between 60 and 70 years old). Amyloid level is not the only biomarker
to consider for a precise diagnosis, but it is the earliest one that has been found. PET
tracers as 18F-Flutemetamol, 18F-Fluorbetaben and 18F-Fluorbetapir allow to detect
the brain zones of amyloid accumulation, but also to quantify such phenomenon.
At present day clinical practice include PET imagingwith one of the above tracer, which
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is visually and qualitatively inspected by trained experts. The aim of the inspection
is to exclude AD, otherwise the patient has to undergo other exams. Several semi-
quantitative [3, 5, 6], quantitative [1, 8] or kinetics[2] methods have been proposed in
the past.
In this work a quantitative method is proposed and compared with qualitative results.
Thismethod uses both early and late acquisitions in order to take kinetics into account.
It has been applied to a particular tracer, but it can be applied to different amyloid
tracers and can be helpful for qualitative assessments too.
6.2 Materials andMethods
6.2.1 Patients
A total number of 86 subjects was enrolled in the study, 53 negatives and 33 positives
according to the qualitative analysis made by two independent experts. Conflicting
cases were solved by a third independent expert. All patients gave written informed
consent.
6.2.2 PET/MRI
PET static images were taken in two phases: an early phase PET1 and a later-acquired
PET2. Only a T1-weighted MPRAGEMRI (MRI2) sequence was acquired concurrently
to the latter PET. The motivation of this choice is to normalize for the uptake early
phase of the tracer kinetics.
6.2.3 Pipeline
Since PET images available are static, the pipeline applied in this study is simpler to
the one used in the previous Chapter, see Fig. 6.1Flowchart for the pipeline followed in
this study. Edema segmentation was not included, as it only affects the decision about
keeping or not the final aMRGlu value. For shake of simplicity also the registration of
freesurfer-obtained atlas to BIC space is omitted.figure.caption.51. Instead of using a
thoracic PET/MRI for computing the plasma glucose, now the average PET value per
VOI is computed with SUVR using the cerebellar cortex as reference tissue.
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PET 1
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MRI 2
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PT1 PT2
Figure 6.1: Flowchart for the pipeline followed in this study. Edema segmentation was not
included, as it only affects the decision about keeping or not the final aMRGlu value. For shake
of simplicity also the registration of freesurfer-obtained atlas to BIC space is omitted.
The resulting numerical value will be called
R1 =
PT1
PT1(cerebel lum ctx)
for the early SUVR and
R2 =
PT2
PT2(cerebel lum ctx)
for the later one.
Other biomarkers have been computed as the slope
Rslope =
R2−R1
∆t
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where ∆t is the difference in minutes between the early and the later acquisition, and
the Relative WM Index (RWMI)
RWMI = 100
PET2−PET2(WM)
PET1−PET1(WM)
.
The idea between these last two indexes is to normalize the later PET values with
respect to the uptake phase. The WM is taken as reference in RWMI because a recent
publication[4] suggested that amyloid PET uptake in the cortex would greater than
than WM uptake (so the denominator is likely to be positive), but later the PET in
cortical areas would take values smaller than WM values in amyloid-negative sub-
jects, differently from amyloid-positives. In a perfect-world enviromnent RWMI will
plausibly be less than zero for negatives and greater than zero for positives. This does
not always happen in practice. Nevertheless RWMI will be proven as a predictive
biomarker in discern amyloid-positive and negative.
Other biomarkers as the Cortical Thickness for cortical VOIs and Volume inmm3 come
for free with using recon-all script from Freesurfer.
6.2.4 Statistics
When comparing two groups, their normality was checked using Shapiro-Wilk test.
Then, the two groups were compared using unpaired t-test andMann-Withney test.
Linear correlation was computed using Spearman’s rho value. Significance level was
set to 0.01.
When testing a biomarker predictivity, K-means clustering was performed in scikit-
learn0.16.
From the resulted predicted values of positivity (0 for negatively-predicted subjects,
1 for positive) True/False positive rates (tpr, fpr) were computed taking the expert’s
rate as reference. The relative Receiver Operator Curve (ROC) and its Area Under the
Curve (AUC) was computed for Lobes. AUC is equal to 1 for the perfect predictor, 0.5
for the random guesser and 0 for the perfect liar.
Anothermethod has been tried to guess positivity frombiomarkers, Fig. 6.2Scheme
for age-independent z-score.figure.caption.52. A biomarker y for a negative subject
has been fitted with the subject’s age x as y =mx + q and the biomarker has been
corrected for age, y ′ = y−mx. Mean and standard deviation µ,σ have been calculated
for y ′. A new subject’s biomarker with value y¯ and age x¯ was then age-corrected
y¯ ′ = y¯ −mx¯ and its z-score was calculated as
z =
y¯ ′−µ
σ
.
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6.4 Discussion
It is not strange that the differences in Cth (wich measures neurodegeneration) and
R1 (uptake) are not significative, as the age of the two groups is undistinguishable.
The correlation of negative subjects’ biomarkers with age proves that age-independent
analysis, as in our description, is a reasonable choice. The R2 biomarkers is in practice
very similar to the criterium used by experts for rating PET images, and in fact it
shows a better coherence with the assessment given. This does not necessarily mean
that Rslope and RWMI are actually less reliable in classifying between positive and
negatives. It is interesting to observe for instance that Rslope shows in some negative
subject higher value in areas that are histologically known to be early affected by
abnormal amyloid accumulation as mesiotemporal, hippocampal and enthorinal
cortex. In order to confirm such intuition however, a further study is needed.
6.5 Conclusions and FutureWork
Cerebellar GMSUVR, orR2 seems to delineate and predict amyloid positive vs negative
group better than other biomarkers proposed in this work. However other biomarkers,
obtained considering also the uptake phase, as Rslope or RWMI , have shown (espe-
cially the first one) a good predictivity and worths a further study in the future.
This work could benefit from longitudinal follow-up, in order to better delineate
the ongoing biomarkers in normal aging as in AD patients. Another option in dis-
cussion is to extend such approach to PET/CT images, easier to find as the machine
is more diffused in Italian Hospitals, with the drawback that in brain images CT are
harder to segment in a reliable way thanMRI.
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Chapter 7
High and LowGrade Brain Tumors in
PET/MRI
Not long after my grandmother died, my computer crashed and I
lost the journal I had kept of her [...].
I was ashamed of my need to translate into words the physical
intimacy of her death, so while I was writing it, I took comfort in the
fact that my journal did and did not exist. It lived in limbo, much as
my grandmother had as she lay unconscious.
But then my computer crashed and I wanted my words back. I
mournedmy journal alongside my grandmother. That secondary
cyber loss brought back the first bodily loss andmade it final. The
details of her dying no longer lived in a safe interim computer sleep.
My words were gone. Or were they? Friends who knew about such
things assured me that in the world of computers, nothing is ever
really gone.
Jonathan Rosen, The Talmud and the Internet
H
igh grade Brain Tumors can lead to patient passing out in a relatively short
time[4, 3]. The treatment, consisting in neurosurgery, radiotherapy and
chemotherapy can extend the survival time by somemonths. All the steps
of the treatment rely on Imaging for detecting the tumor, studying a strat-
egy for surgery and detecting post-surgery tumor relapses[2, 7, 6, 5]. This chapter
contains a longitudinal study involving 12 patient, with pre- and post-surgery PET/RM
images.
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7.2.2 PET/MRI
Similarly to SM study, T1 and FLAIR sequences of the brain and STIR of the thorax
were acquired for each patient at each session. Two PET scans in thorax and brain
were acquired to compute plasma glucose with good precision. The scanning protocol
was identical to the one explained in SM study, except that DIR sequence was not
preformed.
7.2.3 Pipeline
Also the pipeline, Fig. 7.3Flowchart for the pipeline followed in this study. Edema
segmentation was not included, as it only affects the decision about keeping or not
the final aMRGlu value.figure.caption.58 was similar to the one used in MS study, with
three main differences:
1. Instead of lesion segmentation, edema and tumor lesion area was manually
segmented from FLAIR sequence. This mask was used to exclude areas with
a percentage of edema greater then 5% and to automatically detect homo-
lateral and contra-lateral hemispheres of the brain1. The surrounding area was
included in the VOI to avoid mistaking tumor uptake for normal brain activity,
see fig. 7.2A MRI T1 (left) and aligned FLAIR (right) with edema VOI (in red
overlay), before (A,B) and after (C,D) surgical intervention.figure.caption.57.
2. Due to the presence of the tumor, automated softwares for brain segmentation
would likely fail. It was chosen instead to use a probabilistic atlas defined
in MNI152 space, over 37 healthy subjects. The chosen atlas was Fsl Harvard
Oxford Lateralized Cortical (HOLC) Atlas[1], consisting in 48 left/48 right cortical
labels and 20 left/20 right subcortical labels. The T1MRI image was registered
to the template MNI152, and the inverse registration was applied to HOLC Atlas.
The resulting Atlas was used for PVC of the aligned PET image.
3. The probabilistic HOLC Atlas was converted to a simple, deterministic atlas, us-
ing themaximumprobability criterium, explained in Eq. 4.1A formal introductionequation.4.1.1
with threshold equal to 0.1; the resulting VOIs were used to measure PET signal
and the Patlak method was used to obtain aMRGlu for each VOI of the Atlas.
1for instance, if the edema area was in the left part of the brain, left hemisphere of the brain was the
homo- and right hemisphere the contra-lateral.
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Figure 7.3: Flowchart for the pipeline followed in this study. Edema segmentation was not
included, as it only affects the decision about keeping or not the final aMRGlu value.
7.2.4 Statistical Analysis
When comparing two groups, their normality was checked using Shapiro-Wilk test.
Then, the two groups were compared using unpaired t-test andMann-Withney test.
7.3 Results
Contralateral hemisphere has resulted to benefit from the intervention more than
homolateral: as can be observerd in Table 7.1Mean values and p-values before-after
neurosurgery in contralateral (left) and homolateral hemispheres. In red, the significa-
tive p-values, less than 0.05.table.caption.59, 13/48 cortical areas have significantly
increased aMRGlu values. No significant increase has been found in homolateral
hemisphere, except for Cuneal Cortex. Considering the different tumor grading, in 5/8
high grades and 3/4 it is possible to observe a increase of aMRGlu in all 48/48 cortical
areas.
7.4 Discussion
This study confirms, in the limits of the low statistical sample size, the positive effects
of surgical intervention in brain tumors. Surprisingly, contralateral hemisphere seem
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Cortical Brain Region Contr. Pre Contr. post p-val Homol. pre Homol. post p-val
Frontal pole. 11.206 14.260 0.124 12.317 12.798 0.791
Insular Cortex 17.174 20.438 0.136 18.184 17.993 0.975
Superior Frontal Gyrus 15.142 18.237 0.149 14.993 17.827 0.295
Middle Frontal Gyrus 14.538 17.813 0.150 14.402 17.658 0.239
Inferior Frontal Gyrus, pars triang. 12.541 16.306 0.091 12.738 13.566 0.684
Inferior Frontal Gyrus, pars operc. 12.999 17.892 0.037 13.964 15.625 0.590
Precentral Gyrus 13.679 17.219 0.066 15.510 17.989 0.387
Temporal Pole 9.890 12.129 0.130 9.243 10.901 0.297
Superior Temporal Gyrus, anterior division 12.594 15.149 0.228 11.968 13.110 0.605
Superior Temporal Gyrus, posterior division 13.296 16.712 0.05 12.872 14.639 0.598
Middle Temporal Gyrus, anterior division 11.389 14.593 0.07 11.926 13.369 0.559
Middle Temporal Gyrus, posterior division 12.073 15.425 0.084 11.711 13.173 0.393
Middle Temporal Gyrus, temporooccipital part 12.563 16.451 0.044 11.950 14.814 0.278
Inferior Temporal Gyrus, anterior division 10.717 15.149 0.07 9.663 12.632 0.119
Inferior Temporal Gyrus, posterior division 10.393 14.652 0.04 10.335 12.171 0.310
Inferior Temporal Gyrus, temporooccipital part 12.294 15.806 0.094 11.971 14.304 0.341
Postcentral Gyrus 13.739 17.581 0.068 13.819 17.165 0.298
Superior Parietal Lobule 14.075 18.100 0.063 14.820 17.819 0.224
Supramarginal Gyrus, anterior division 11.877 14.714 0.114 10.626 12.514 0.507
Supramarginal Gyrus, posterior division 12.795 15.764 0.096 11.761 15.873 0.208
Angular Gyrus 13.733 17.461 0.067 13.508 15.840 0.429
Lateral Occipital Cortex, superior division 13.317 16.344 0.112 12.048 13.645 0.461
Lateral Occipital Cortex, inferior division 12.357 15.047 0.152 10.835 14.488 0.173
Intracalcarine Cortex 15.680 19.470 0.143 18.823 18.017 0.522
Frontal Medial Cortex 14.625 20.398 0.050 15.184 17.259 0.380
Juxtapositional Lobule Cortex 16.070 21.260 0.062 15.602 18.967 0.216
Subcallosal Cortex 14.666 17.416 0.172 13.928 16.701 0.156
Paracingulate Gyrus 17.134 20.458 0.204 18.245 17.520 0.801
Cingulate Gyrus, anterior division 11.732 16.418 0.023 14.015 15.759 0.404
Cingulate Gyrus, posterior division 14.593 19.542 0.048 15.223 17.714 0.487
Precuneous Cortex 16.373 20.476 0.086 13.385 18.549 0.139
Cuneal Cortex 16.923 22.428 0.066 14.111 20.973 0.014
Frontal Orbital Cortex 13.184 18.354 0.025 13.617 16.062 0.281
Parahippocampal Gyrus, anterior division 11.665 14.791 0.07 11.129 13.183 0.286
Parahippocampal Gyrus, posterior division 14.314 17.365 0.069 13.526 15.917 0.446
Lingual Gyrus 14.607 19.149 0.05 13.668 17.262 0.318
Temporal Fusiform Cortex, anterior division 8.158 11.722 0.044 7.882 9.832 0.324
Temporal Fusiform Cortex, posterior division 10.442 14.442 0.033 10.729 13.060 0.340
Temporal Occipital Fusiform Cortex 16.041 20.085 0.046 15.750 18.780 0.438
Occipital Fusiform Gyrus 15.364 19.849 0.051 14.920 18.709 0.225
Frontal Operculum Cortex 15.970 19.363 0.09 15314 18.099 0.572
Central Opercular Cortex 14.760 17.398 0.132 12.976 16.629 0.500
Parietal Operculum Cortex 13.538 16.867 0.041 14.861 16.360 0.767
Planum Polare 11.542 17.091 0.007 11.722 14.934 0.316
Heschl’s Gyrus (includes H1 and H2) 19.193 27.918 0.008 17.811 25.257 0.127
Planum Temporale 17.950 24.699 0.030 17.621 20.259 0.569
Supracalcarine Cortex 18.458 22.267 0.284 20.020 21.082 0.855
Occipital Pole 10.300 12.233 0.205 8.780 10.786 0.196
Table 7.1: Mean values and p-values before-after neurosurgery in contralateral (left) and homo-
lateral hemispheres. In red, the significative p-values, less than 0.05.
98

100
Bibliography
[1] RS Desikan, F Sègonne, et. al, An automated labeling system for subdi-
viding the human cerebral cortex on MRI scans into gyral based regions of
interest, Neuroimage, 2006.
[2] L Douw, et al. Cognitive and radiological effects of radiotherapy in patients
with low-grade glioma: long-term follow-up, Lancet Neurol. 2009.
[3] A Hutter, KE Schwetye, AJ Bierhals, RCMcKinstry, Brain neoplasms epi-
demiology, diagnosis, and prospects for cost-effective imaging, Neuroimag-
ing Clin N Am, 2003.
[4] Y Kienast, F Winkler, Therapy and prophylaxis of brain metastases, Expert
Rev Anticancer Ther. 2010.
[5] YY Lee, P Van Tassel, Intracranial oligodendrogliomas: imaging findings
in 35 untreated cases, AJR Am J Roentgenol. 1989.
[6] PE Ricci, Imaging of adult brain tumors, Neuroimaging Clin N Am, 1999.
[7] R Stupp , WP Mason, MJ van den Bent, et-al., Radiotherapy plus con-
comitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med,
2005.
101
102
